Background Because follicular lymphoma (FL) patients have heterogeneous outcomes, the
FL international prognostic index (FLIPI) was developed to risk-stratify patients and to predict …

The Follicular Lymphoma International Prognostic Index (FLIPI) was developed to predict
prognosis of patients with follicular lymphoma (FL). However, it was based on different …

Purpose Patients with follicular lymphoma (FL) registered in the F2-study and initially
managed without treatment were analyzed to describe the presentation and outcome of a …

Purpose The optimal management of stage I follicular lymphoma, according to consensus
guidelines, is based on uncontrolled experiences of select institutions. Diverse treatment …

Follicular lymphoma (FL) is a heterogeneous disease with varying prognosis owing to
differences in clinical, laboratory, and disease parameters. Although generally considered …

Recent advances in follicular lymphoma (FL) have resulted in prolongation of overall
survival (OS). Here we assessed if early events as defined by event‐free survival (EFS) at 12 …

Abstract Background The revised World Health Organization (WHO) classification maintains
a histological grading system (grades 1–3) for follicular lymphoma (FL) and subdivides …

Purpose Twenty percent of patients with follicular lymphoma (FL) experience progression of
disease (POD) within 2 years of initial chemoimmunotherapy. We analyzed data from the …

Follicular lymphoma (FL) is one of the most common types of non-Hodgkin's lymphoma. It is
usually diagnosed at an advanced stage, for which many treatment options exist, however …

In follicular lymphoma (FL), no prognostic index has been built based solely on a cohort of
patients treated with initial immunochemotherapy. There is currently a need to define …